NASDAQHealth CareMedical DevicesSnapshot 2026-07-23
Reading MASI? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →A long-form read on the 1–3 year hold thesis. Slower and deeper than the daily snapshot — it refreshes only when the evidence moves.
This is a long-term thesis on a company that is currently loss-making but has shown strong recent financial performance. The investment is characterized by moderate risk and a focus on improving revenue growth and profit margins.
The market currently prices MASI at a durable premium compared to its peers, indicating high expectations. However, this premium appears unjustified given the company's ongoing losses and mixed management execution.
Management's focus on revenue growth and improving gross profit margins suggests a potential for better performance in the coming quarters. However, the company has faced consecutive earnings misses, which adds a layer of uncertainty.
The thesis hinges on the performance of sector bellwethers like ABT, SYK, and MDT, as their results could significantly impact MASI's momentum. Additionally, any changes in guidance from MASI could lead to a negative shift in market sentiment.
In the next 1 to 3 years, MASI's performance will depend on its ability to execute on growth initiatives and navigate sector dynamics. Not investment advice.
The most important moves since the prior daily snapshot.
Mixed, the news cuts both ways. The acquisition of Danaher is still on track. However, Danaher's mixed results may affect confidence in the acquisition. Additionally, FDA approval for a new patient monitor could boost revenue growth.
as of 2026-07-23
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Why it matters: Revenue growth is important for Masimo's success. It shows the company's market strength.
Confirms:Q2 revenue growth is more than the guidance of about $1,523 million.
Disproves:Q2 revenue growth is less than the guidance, showing ongoing problems.
Why it matters: Maintaining strong revenue growth supports Masimo's growth strategy. It shows the company is on track.
Confirms:Revenue reported above $403.6M in the next earnings report.
Disproves:Revenue below $372M shows growth is slowing down.
Why it matters: Approval is key for Masimo to complete the merger and unlock future growth.
Confirms:Approval comes from the right government groups before the merger closes.
Disproves:Approval is denied or delayed longer than expected.
Why it matters: Approvals are important to finish the merger. Delays can change the timeline.
Confirms:All needed approvals are granted by the end of Q3 2026 without delays.
Disproves:If approvals are delayed or denied, the merger timeline will be pushed back.
Why it matters: Finishing the acquisition on time shows management's plan for growth. It builds market trust.
Confirms:The merger officially closes by the end of Q3 2026.
Disproves:The merger is postponed or fails to close by the end of Q3 2026.
Why it matters: Revenue growth below 10% would signal a slowdown in the company's performance. This could impact investor confidence.
Confirms:Q3 revenue growth reported below 10% year over year.
Disproves:Q3 revenue growth remains at or above 10% year over year.
Why it matters: Delays may show financial problems. This could hurt investor trust.
Confirms:The Credit Agreement ends without any delays.
Disproves:Delays or problems happen when ending the Credit Agreement.
Why it matters: Higher gross profit margins show better cost control and profit. This may help investor feelings.
Confirms:Gross profit margins are higher than last quarter.
Disproves:Gross profit margins decline or remain flat compared to the previous quarter.
Why it matters: Better margins mean better cost control. This is important for making money long-term.
Confirms:Gross profit margins reported above the previous $250.8M in the next earnings report.
Disproves:Gross profit margins decline or stay below $250.8M, indicating cost issues.
Why it matters: A drop in sector growth could impact Masimo's performance. It signals broader industry challenges.
Confirms:Sector revenue growth below average shows a slowdown.
Disproves:Sector revenue growth stays steady or gets better, helping Masimo grow.
Why it matters: Revenue growth shows how well the company adapts after the merger.
Confirms:Q2 2026 revenue growth exceeds 10% year over year.
Disproves:Q2 2026 revenue growth falls below 5% year over year.
Why it matters: Meeting revenue growth goals shows good execution of plans after the buyout.
Confirms:Q2 revenue growth meets or exceeds 9% year over year.
Disproves:Q2 revenue growth falls below 5% year over year.
